103285-22-9

• 常用中文名：DMT保护性-2'-甲氧基尿苷
• 常用英文名：2'-O-Methyl-5'-O-DMT-Uridine;DMT-2'-OMe-U
• CAS号：103285-22-9
• 分子式：C₃₁H₃₂N₂O₈
• 分子量：560.59
• 相关类别： 生物化工 核苷类药物 核苷中间体
• 发布时间：2018-12-01 10:39:50
• 更新时间：2026-07-01 08:13:36
• 5'-O-(4,4'-二甲氧基三苯基)-2'-O-甲基尿苷是尿苷类似物。尿苷具有潜在的抗癫痫作用,其类似物可用于研究抗惊厥和抗焦虑活性,以及开发新的抗高血压药物[1]。

名称

• 中文名: 1-((2R,3r,4r,5r)-5-((双(4-甲氧基苯基)(苯基)甲氧基)甲基)-4-羟基-3-甲氧基四氢呋喃-2-基)嘧啶-2,4(1h,3h)-二酮
• 英文名: 1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione
• 中文别名: 5'-O-(4,4'-二甲氧基三苯甲基)-2'-O-甲基尿苷; (VOI)5-O-(4,4-二甲氧基三苯甲基)-2'-甲氧基尿苷; 1-[(2R,3R,4R,5R)-5-[[双(4-甲氧基苯基)-苯基甲氧基]甲基]-4-羟基-3-甲氧基氧代草烷-2-基]嘧啶-2,4-二酮; 1-((2R,3R,4R,5R)-5-((双(4-甲氧基苯基)(苯基)甲氧基)甲基)-4-羟基-3-甲氧基四氢呋喃-2-基)嘧啶-2,4(1H,3H)-二酮; 1-[(2R,3R,4R,5R)-5-[[双(4-甲氧基苯基)-苯基甲氧基]; 5'-DMT-2'-甲氧基尿苷; 5'-O-(4,4'-二甲氧基三苯甲基)-2'-O-CHEMICALBOOK甲基尿苷; 5'-O-(二甲氧基三苯甲基)-2'-O-甲基尿苷; 5'-DMTR-2'-甲氧基尿苷; 5'-O-(4,4'-二甲氧基三苯基甲基)-2'-甲氧基尿苷; 5'-O-DMT-2'-O-甲基尿苷; 5'-O-DMT-2'-甲氧基尿苷
• 英文别名: oligoadenylate Synthetase 1, 40/46kD, IFI-4, OIAS, OIASI) (Biotin); HG1364; 5'-O-DMT-2'-O-METHYL-URIDINE; cyclic Phosphodiesterase B, Cyclic GMP-inhibited Phosphodiesterase B, HcGIP1); nucleotidase, Thiamine Monophosphatase, TMPase) (PE); 5'-DMT 2'-O-methyl uridine; cyclic Monophosphate) (HPLC); cyclic phosphodiesterase 4C, PDE21); deoxyinosine (HPLC); Dibromoacetophenone ≥ P1,P3-triphosphate hydrolase, Dinucleosidetriphosphatase, Tumor Suppressor Protein, AP3Aase, FRA3B); nucleotidase 1, PAP-inositol 1,4-phosphatase, PIP); 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-methyl-uridine; 8-d3; dimethoxytrityl) thymidine (synthetic) (TLC); cyclic phosphodiesterase 4B, DPDE4, PDE32) (APC); cyclic phosphodiesterase 8B, Cell proliferation-inducing gene 22 protein); NT, eN, eNT, NT5, NT5E, NTE, Purine 5 Prime Nucleotidase); Cyclic-AMP and -GMP Phosphodiesterase 11A, cAMP and cGMP Phosphodiesterase 11A); 5'-O-(DIMETHOXYTRITYL)-2'-O-METHYLURIDINE; trifluoroacetamidocytidine; cyclic nucleotide phosphodiesterase 1B, PDE1B1, PDES1B); P1,P6-hexaphosphate Hydrolase 1, Nucleoside Diphosphate-linked Moiety X Motif 3, Nudix Motif 3, DIPP, DIPP1); 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-O-METHYLURIDINE; DMT-2'-OMe-U; DMT-2'-O-METHYLURIDINE; anhydrouridine; cyclic Phosphodiesterase Subunit Alpha, Phosphodiesterase 6C, cGMP-specific, Cone, Alpha Prime); 2'-O-methyl-5"-O-dimethoxytrityl uridine; Nucleotidase, Cytosolic III (NT5C3); PDE10A, BioAssay™ 1-((2R,3R,4R,5R)-5-((bis(4-Methoxyphenyl)(phenyl)Methoxy)Methyl)-4-hydroxy-3-Methoxytetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione; oligoadenylate Synthase-like Protein, p59 OASL, p59OASL, Thyroid Rector-interacting Protein 14, TR-interacting Protein 14, TRIP-14, TRIP14); pyrophosphohydrolase, (ppGpp)ase, MESH1); cyclic Phosphodiesterase 9A, FLJ90181, HSPDE9A2); PDE3B, BioAssay™ 5'-O-DMT-2'-O-methyluridine; Exonuclease TREX1, AGS1, CRV, DNase III, DRN3, HERNS); bisphosphate, Triethylammonium Salt (Biotin); cyclic phosphodiesterase subunit delta, Protein p17); P1,P4-tetraphosphate asymmetrical hydrolase, Nucleoside diphosphate-linked moiety X motif 2); cyclic Phosphodiesterase B, CGIPDE1, CGIP1, Cyclic GMP-inhibited Phosphodiesterase B, CGI-PDE B); Methoxylaudanosine; dimethoxybenzyloxy)phenylboronic acid; Uridine, 5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-O-Methyl; 5'-O-DMT-2'-O-methyl-D-uridine; deoxy-b-D-ribofuranosyl]guanine; terthiophene]-5-cbaldehyde; cyclic Phosphodiesterase 10A); nucleotidase 1, PIP, PAP-inositol-1,4-phosphatase, HEL20); bisphosphate nucleotidase 1, PIP); nucleotidase 1, PAP-inositol 1,4-phosphatase); Bis-(S)-phosphate; cyclic Nucleotide Phosphodiesterase 1A, Cam-PDE 1A, 61kD Cam-PDE, hCam-1, M26303) (FITC); cyclic Phosphodiesterase A, Cyclic GMP-inhibited Phosphodiesterase A, CGI-PDE A) (FITC); deoxyadenosine ≥ tri-O-tert-butyldimethylsilyl-b-D-ribofuranosyl)-imidazo[4,5-c]pyridine; oligoadenylate synthase 1, E18/E16, p46/p42 OAS); d4 3-O-β cyclic phosphodiesterase 4C, PDE21) (PE); cyclic Phosphodiesterase 10A, FLJ11894, FLJ25677, HSPDE10A) (PE); )oligo(A) Synthase 3, A Synthase 3, p100 OAS, p100OAS, P/OKcl.4) (FITC); di-O-tritylguanosine

物化性质

• 分子式: C₃₁H₃₂N₂O₈
• 分子量: 560.59
• 精确质量: 560.21600
• PSA: 121.24000
• LogP: 2.83580
• 外观性状: Powder | White to Pale Yellow
• 储存条件: Store dry at 2-8°C

生物活性

• 描述: 5'-O-(4,4'-二甲氧基三苯基)-2'-O-甲基尿苷是尿苷类似物。尿苷具有潜在的抗癫痫作用,其类似物可用于研究抗惊厥和抗焦虑活性,以及开发新的抗高血压药物[1]。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> 细胞周期/DNA损伤 >> 核苷抗代谢药/类似物
• 参考文献:

  [1]. Connolly GP, et al. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci. 1999 May;20(5):218-25.

合成路线

109-88-6 173170-12-2 ~65% 103285-22-9

文献：Buettner, Lea; Seikowski, Jan; Wawrzyniak, Katarzyna; Ochmann, Anne; Hoebartner, Claudia Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 20 p. 6171 - 6180

40615-36-9 ~99% 103285-22-9

文献：ISIS Pharmaceuticals, Inc. Patent: US5914396 A1, 1999 ;

40615-36-9 2140-76-3 ~90% 103285-22-9

文献：Barbeyron, Renaud; Wengel, Jesper; Vasseur, Jean-Jacques; Smietana, Michael Monatshefte fur Chemie, 2013 , vol. 144, # 4 p. 495 - 500

3736-77-4 ~% 103285-22-9

文献：Bioorganic and Medicinal Chemistry, , vol. 21, # 20 p. 6171 - 6180

58-96-8 ~% 103285-22-9

文献：Bioorganic and Medicinal Chemistry, , vol. 21, # 20 p. 6171 - 6180